Test the intelligence before we ask the market to trust it.
A focused seven day test for clinicians, pharmacists, medicines governance professionals, regulated clinics and life sciences organisations.
Closed beta position
The first cohort is deliberately small and free of charge. Participation does not imply NICE endorsement, NHS approval, clinical validation or a commercial relationship.
WHAT TESTERS RECEIVE
Full access to the current evidence platform
The 25 molecule readiness database and primary source links
UK and Ireland access pathways and regulatory distinctions
A short orientation and a direct route to report corrections
A summary of improvements made from cohort feedback
WHAT WE ASK IN RETURN
A hard test, not polite approval
Test three genuine or representative professional questions
Check whether the source trail supports the wording used
Identify uncertainty, missing context and friction
Complete a short closeout review
THE SEVEN DAY TEST
Small enough to complete. Serious enough to learn from.
Day 1
Choose the questions
Select three professional questions, at least one molecule record and the relevant UK or Ireland pathway.
Days 2 to 5
Use the evidence
Test the search, source links, status distinctions and readiness record in a real or representative workflow.
Days 6 to 7
Challenge the result
Report anything unclear, incomplete or difficult to verify and estimate the time saved.
Closeout
Give candid feedback
A short review records what was useful, what was missing and whether the platform should progress.
FEEDBACK AND TESTIMONIALS
Your feedback remains yours.
We may ask whether a tester is willing to provide a short attributed or anonymous statement. Nothing will be quoted, named or published without separate written approval of the exact wording and attribution.
Apply to test the beta
Tell us the professional decision or question you would use Peptide Readiness to examine.
Organisation test
For a clinic, pharmacy, healthcare organisation, life sciences team or professional evidence function.
UK and Ireland Peptide Readiness Brief
Join the briefing list for evidence, regulatory and market readiness changes. Consent is explicit and separate from a beta application.
Commercial relationships cannot influence evidence grading, regulatory descriptions or readiness scoring. Applications are reviewed and submission does not guarantee access.